473 related articles for article (PubMed ID: 26700622)
1. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
2. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IA; Greenberg NM; Elgavish A
J Nutr; 2005 May; 135(5):989-95. PubMed ID: 15867270
[TBL] [Abstract][Full Text] [Related]
3. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
5. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
6. Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.
Wan L; Tan HL; Thomas-Ahner JM; Pearl DK; Erdman JW; Moran NE; Clinton SK
Cancer Prev Res (Phila); 2014 Dec; 7(12):1228-39. PubMed ID: 25315431
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin has a protective role in prostate tumor development in mice.
Danzaki K; Kanayama M; Alcazar O; Shinohara ML
Eur J Immunol; 2016 Nov; 46(11):2669-2678. PubMed ID: 27601131
[TBL] [Abstract][Full Text] [Related]
8. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
Pittoni P; Tripodo C; Piconese S; Mauri G; Parenza M; Rigoni A; Sangaletti S; Colombo MP
Cancer Res; 2011 Sep; 71(18):5987-97. PubMed ID: 21896641
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
10. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
11. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.
Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ
Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003
[TBL] [Abstract][Full Text] [Related]
12. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
13. Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.
Jachetti E; Rigoni A; Bongiovanni L; Arioli I; Botti L; Parenza M; Cancila V; Chiodoni C; Festinese F; Bellone M; Tardanico R; Tripodo C; Colombo MP
Mol Cancer Ther; 2017 Feb; 16(2):365-375. PubMed ID: 27980106
[TBL] [Abstract][Full Text] [Related]
14. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.
Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH
Cancer Res; 2006 Feb; 66(3):1712-20. PubMed ID: 16452231
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
18. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
19. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
[TBL] [Abstract][Full Text] [Related]
20. Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
Corbin JM; Overcash RF; Wren JD; Coburn A; Tipton GJ; Ezzell JA; McNaughton KK; Fung KM; Kosanke SD; Ruiz-Echevarria MJ
Prostate; 2016 Jan; 76(1):97-113. PubMed ID: 26417683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]